Poster Abstract Session:
130. Antimicrobial Agents: Novel Agents
Friday, October 9, 2015: 12:30 PM-2:00 PM
Room: Poster Hall

Learning Objectives:


Tracks: Adult ID

Discovery of OspA-specific human monoclonal antibodies reactive against a broad range of Borrelia species for the prevention of Lyme disease
Yang Wang, MD PhD ; Naomi Boatright, BA ; Andrew Sadowski, BA ; William Thomas Jr., PhD ; Mark S. Klempner, MD
  • 763_IDWPOSTER.pdf (268.5 kB)
  • 764
    Human monoclonal antibodies specific for OspA prevent Lyme borreliosis in mice
    Yang Wang, MD PhD ; Aurélie Kern, PhD ; Andrew Sadowski, BA ; Naomi K. Boatright, BA ; Linden Hu, MD ; William Thomas Jr., PhD ; Mark S. Klempner, MD
  • 764_IDWPOSTER.pdf (199.1 kB)
  • 765
    Drug Interaction Profile of GS-5806
    Yan Xin, Ph.D. ; Seth Toback, M.D. ; Winnie Weng, PhD ; Krysia Grycz, MS ; Eugene Eisenberg, PhD ; Jonna Weston, MS ; Bernard Murray, PhD ; Jason Chien, M.D. ; Srini Ramanathan, PhD ; Jeffrey Silverman, PhD
  • Bio Xin DDI IDWeek.pdf (141.3 kB)
  • 767
    S-649266, a Novel Siderophore Cephalosporin: In Vitro Activities against Multidrug-Resistant and Carbapenem Resistant Gram-Negative Pathogens in an in vitro Pharmacodynamic Model
    Masakatsu Tsuji, Ph.D ; Rio Nakamura, bachelor's degree ; Sachi Kanazawa, Ph.D ; Shuhei Matsumoto, master's degree ; Takafumi Sato, Ph.D ; Yoshinori Yamano, Ph.D
  • 767_IDWeek2015_final.pdf (4.2 MB)
  • 768
    Evaluation of the pharmacokinetics of GS-5806 in healthy Japanese and Caucasian subjects
    Yan Xin, Ph.D. ; Seth Toback, M.D. ; Winnie Weng, PhD ; PJ Costales, BA ; Jason Chien, M.D. ; Jeffrey Silverman, PhD ; Srini Ramanathan, PhD
  • Bio Xin Ethnicity IDWeek.pdf (88.7 kB)
  • 769
    Safety, Tolerability and Pharmacokinetics (PK) Following Single and Multiple Ascending Dosing of AL-8176 In Healthy Volunteers (HV)
    Matthew Mcclure, MD ; Abbie Oey, BS ; John Fry, RN ; Qingling Zhang, PhD ; Lawrence Blatt, PhD ; Leo Beigelman, PhD ; Julian Symons, D.Phil ; Nicolas Fauchoux, MD ; Haydee Ramos, MD, PHD ; Alain Patat, MD ; Sushmita Chanda, PhD
    Novel Antiviral prevents Viral Upper Respiratory Infections in vitro and in vivo
    Frank Esper, MD ; Matthew Dimaano, B.S. ; Daniel Popkin, MD, PhD ; Hisashi Fujioka, PhD ; Pranab Mukherjee, PhD ; Mahmoud Ghannoum, PhD, FIDSA
    Treatment of Methicillin-Resistant bacteria
    Dghk Sankey, md ; Sharmin Naaz, PhD
    Results of a Global Phase 3 Study of Delafloxacin (DLX) Compared to Vancomycin with Aztreonam (VAN) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
    Sue Cammarata, MD ; Janis Gardovskis, MD ; Brett Farley, MD ; Eugene Sun, MD ; Megan Quintas, BA ; Laura Lawrence, BS ; John Pullman, MD
    S-649266, a Novel Siderophore Cephalosporin: In Vitro Activity against Gram-Negative Bacteria Isolated in Japan including Carbapenem Resistant Strains
    Masakatsu Tsuji, Ph.D ; Takahiro Yamaguchi, bachelor's degree ; Rio Nakamura, bachelor's degree ; Tsukasa Ito-Horiyama, master’s degree ; Takafumi Sato, Ph.D ; Yoshinori Yamano, Ph.D
    In vitro activity of Ceftazidime-Avibactam (CAZ-AVI) against 511 Gram-Negative Clinical Isolates obtained from cancer patients
    Ray Hachem, MD, FIDSA ; Ruth Reitzel, MS ; Kenneth Rolston, MD, FIDSA ; Issam Raad, MD, FACP, FIDSA, FSHEA
  • CAZ-AVI.pdf (495.6 kB)
  • 782
    Activity of Gallium (III) Compounds Against Biofilms of Multidrug-Resistant Isolates of Acinetobacter baumanni
    David Chang, MD ; Rebecca Garcia, BA ; Kevin S. Akers, MD, FIDSA ; Joseph Wenke, PhD ; Carlos Sanchez Jr., PhD
    Outcomes in Obese Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in a Trial Comparing Delafloxacin (DLX)  to Vancomycin/Aztreonam (VAN)
    Lajos Kemény, MD ; Christopher Lucasti, MD ; Eugene Sun, MD ; Megan Quintas, BA ; Laura Lawrence, BS ; Sue Cammarata, MD
  • 2015 302 Obese_data final.pdf (203.7 kB)
  • 784
    Activity of Eravacycline Against Anaerobic Bacteria from Europe Collected in 2013-14
    Ian Morrissey, PhD ; Joyce Sutcliffe, PhD ; Meredith Hackel, PhD, MPH ; Stephen Hawser, PhD
    Single Dose Treatment with Dalbavancin for Acute Bacterial Skin and Skin Structure Infection
    Michael Dunne, MD ; Sailaja Puttagunta, MD ; Philip Giordano, MD ; Dainis Krievins, MD PhD ; Michael Zelasky, MS ; James Baldasarra, MD
    Dalbavancin: A Nationwide Outpatient Experience in Physician Office Infusion Centers (POICs)
    Lucinda J. Van Anglen, PharmD ; Robin H. Dretler, MD, FIDSA ; Quyen Luu, MD ; Ramesh V. Nathan, MD ; Barry Statner, MD, FRCPC, FIDSA ; Fernando S. Alvarado, MD, MPH & TM ; Claudia P. Schroeder, PharmD, PhD
    Comparative In-Vitro Activity of Nemonoxacin Against Staphylococcus aureus
    Andrey Dekhnich, MD, MSc, PhD ; Roman Kozlov, MD, MSc, PhD ; Marina Sukhorukova, MD, MSc, PhD ; Mikhail Edelstein, PhD ; Mikhail Samsonov, MD, MSc, PhD
  • IDSA_2015.pdf (720.5 kB)
  • 788
    Growth Inhibitory Effect of Cerivastatin Against Yeasts and Aspergillus fumigatus
    Haidee Custodio, MD ; Tiffany Norton, MS ; Jarrod Fortwendel, PhD
    Sertraline Demonstrates Fungicidal Activity Against Coccidioides immitis In Vitro
    Simon Paul, M.D. ; Roger Mortimer, MD ; Marilyn Mitchell, MT(ASCP)MS
    Enhanced Consolidation Therapy With High-Dose Fluconazole and Sertraline Ameliorates Negative Outcomes Associated with Persistent CSF Culture Positivity in Cryptococcal Meningitis
    Mahsa Abassi, DO ; Joshua Rhein, MD ; Bozena Morawski, MPH ; Kathy H. Hullsiek, PhD ; Lillian Tugume, MBChB ; Henry Nabeta, MBChB ; Reuben Kiggundu, MBChB ; Andrew Akampurira, BS ; Darlisha Williams, MPH ; David Meya, MMed ; David Boulware, MD, MPH

    CME Credits:

    ACPE Credits:

    ACPE Number:

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.